Fleury (BSP:FLRY3) EBIT: R$1,511 Mil (TTM As of Mar. 2026)


BSP:FLRY3 Fleury SA BSP:FLRY3
91 GF Score
Price R$15.61
GF Value R$17.41
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fleury EBIT?

Fleury BSP:FLRY3 +1.04% 91 EBIT is R$1,511 Mil as of Mar. 2026. GuruFocus rates BSP:FLRY3 with a GF Score™ of 91/100 and a GF Value™ of R$17.41 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Fleury's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was R$426 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was R$1,511 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fleury's annualized ROC % for the quarter that ended in Mar. 2026 was 12.22%. Fleury's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 52.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fleury's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.82%.


Fleury  (BSP:FLRY3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Fleury's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1534.616 * ( 1 - 21.8% )/( (9719.017 + 9917.978)/ 2 )
=1200.069712/9818.4975
=12.22 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13220.481 - 1339.073 - ( 2162.391 - max(0, 2245.68 - 4421.465+2162.391))
=9719.017

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13325.654 - 1257.471 - ( 2150.205 - max(0, 2175.756 - 4650.338+2150.205))
=9917.978

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Fleury's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1704.02/( ( (2477.846 + max(564.229, 0)) + (2434.625 + max(972.484, 0)) )/ 2 )
=1704.02/( ( 3042.075 + 3407.109 )/ 2 )
=1704.02/3224.592
=52.84 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1747.166 + 180.702 + 331.206) - (1339.073 + 0 + 355.772)
=564.229

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2005.869 + 150.818 + 343.446) - (1257.471 + 0 + 270.178)
=972.484

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Fleury's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1511.434/11787.854
=12.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fleury EBIT Related Terms


Fleury EBIT Historical Data

* Premium members only.

The historical data trend for Fleury's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fleury EBIT Chart

Fleury Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 689.83 818.55 1,008.65 1,331.96 1,476.94

Fleury Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 391.51 362.84 428.41 294.18 426.01

BSP:FLRY3 vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Fleury's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fleury EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fleury's EV-to-EBIT falls into.


BSP:FLRY3
91GF Score
Fleury SA BSP:FLRY3
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fleury EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,511 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of R$1,511 Mil mean?
Fleury (BSP:FLRY3) has a EBIT of R$1,511 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Fleury.
Is Fleury's EBIT too high?
Fleury's current EBIT is R$1,511 Mil. Overall, Fleury has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fleury's EBIT compare to TMO and DHR?
Fleury's EBIT of R$1,511 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Fleury. Fleury's current EBIT is R$1,511 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$17.41, compared to a current price of R$15.61 — trading 10.3% below its estimated fair value. The current EBIT is R$1,511 Mil. Fleury's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current EBIT is R$1,511 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fleury (BSP:FLRY3) Overvalued in 2026?

Based on GuruFocus' analysis, Fleury stock appears to be undervalued. The current stock price of R$15.61 is trading 10.3% below its estimated GF Value™ of R$17.41. GuruFocus considers Fleury to be Modestly Undervalued.

Key valuation signals for BSP:FLRY3:

  • EBIT: R$1,511 Mil
  • GF Value™: R$17.41 vs. price of R$15.61 (10.3% below fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fleury Business Description

Address Avenida Morumbi 8.860, 8th floor, Brooklin, Sao Paulo, SP, BRA, 04703-002
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
91GF Score

Get the complete analysis for BSP:FLRY3

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$15.61
Price
R$17.41
GF Value